31 related articles for article (PubMed ID: 7495782)
1. Immunohistochemical expression of blood group substances and related carbohydrate antigens in breast carcinoma.
Nakagoe T; Fukushima K; Hirota M; Kusano H; Kawahara K; Ayabe H; Tomita M; Kamihira S
Jpn J Cancer Res; 1991 May; 82(5):559-68. PubMed ID: 1905702
[TBL] [Abstract][Full Text] [Related]
2. Insight into Cancer Immunity: MHCs, Immune Cells and Commensal Microbiota.
Wen M; Li Y; Qin X; Qin B; Wang Q
Cells; 2023 Jul; 12(14):. PubMed ID: 37508545
[TBL] [Abstract][Full Text] [Related]
3. Major histocompatibility complex class II in the tumor microenvironment: functions of nonprofessional antigen-presenting cells.
Macy AM; Herrmann LM; Adams AC; Hastings KT
Curr Opin Immunol; 2023 Aug; 83():102330. PubMed ID: 37130456
[TBL] [Abstract][Full Text] [Related]
4. Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I-III small cell lung cancer.
Chen P; Zhao L; Wang H; Zhang L; Zhang W; Zhu J; Yu J; Zhao S; Li W; Sun C; Wu C; He Y; Zhou C
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362829
[TBL] [Abstract][Full Text] [Related]
5. HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy.
Anderson P; Aptsiauri N; Ruiz-Cabello F; Garrido F
Cell Mol Immunol; 2021 Mar; 18(3):556-565. PubMed ID: 33473191
[TBL] [Abstract][Full Text] [Related]
6. Biological Consequences of MHC-II Expression by Tumor Cells in Cancer.
Axelrod ML; Cook RS; Johnson DB; Balko JM
Clin Cancer Res; 2019 Apr; 25(8):2392-2402. PubMed ID: 30463850
[TBL] [Abstract][Full Text] [Related]
7. CD74 regulates complexity of tumor cell HLA class II peptidome in brain metastasis and is a positive prognostic marker for patient survival.
Zeiner PS; Zinke J; Kowalewski DJ; Bernatz S; Tichy J; Ronellenfitsch MW; Thorsen F; Berger A; Forster MT; Muller A; Steinbach JP; Beschorner R; Wischhusen J; Kvasnicka HM; Plate KH; Stefanović S; Weide B; Mittelbronn M; Harter PN
Acta Neuropathol Commun; 2018 Mar; 6(1):18. PubMed ID: 29490700
[TBL] [Abstract][Full Text] [Related]
8. HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.
Seliger B; Kloor M; Ferrone S
Oncoimmunology; 2017; 6(2):e1171447. PubMed ID: 28344859
[TBL] [Abstract][Full Text] [Related]
9. Activation of ERα signaling differentially modulates IFN-γ induced HLA-class II expression in breast cancer cells.
Mostafa AA; Codner D; Hirasawa K; Komatsu Y; Young MN; Steimle V; Drover S
PLoS One; 2014; 9(1):e87377. PubMed ID: 24475282
[TBL] [Abstract][Full Text] [Related]
10. HLA class-II allele frequencies in Turkish breast cancer patients.
Gun FD; Ozturk OG; Polat A; Polat G
Med Oncol; 2012 Jun; 29(2):466-71. PubMed ID: 21373933
[TBL] [Abstract][Full Text] [Related]
11. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.
Knutson KL; Disis ML
Cancer Immunol Immunother; 2005 Aug; 54(8):721-8. PubMed ID: 16010587
[TBL] [Abstract][Full Text] [Related]
12. Expression of c-kit in common benign and malignant breast lesions.
Kondi-Pafiti A; Arkadopoulos N; Gennatas C; Michalaki V; Frangou-Plegmenou M; Chatzipantelis P
Tumori; 2010; 96(6):978-84. PubMed ID: 21388062
[TBL] [Abstract][Full Text] [Related]
13. HLA class II sublocus expression in benign and malignant breast epithelium.
Zuk JA; Walker RA
J Pathol; 1988 Aug; 155(4):301-9. PubMed ID: 2459333
[TBL] [Abstract][Full Text] [Related]
14. Histology and immunophenotype of invasive lobular breast cancer. daily practice and pitfalls.
Varga Z; Mallon E
Breast Dis; 2008-2009; 30():15-9. PubMed ID: 19850991
[TBL] [Abstract][Full Text] [Related]
15. A Critical Assessment of the Association between HLA-G Expression by Carcinomas and Clinical Outcome.
van de Water RB; Krijgsman D; Houvast RD; Vahrmeijer AL; Kuppen PJK
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34361031
[TBL] [Abstract][Full Text] [Related]
16. Different patterns of HLA-DR antigen expression in normal epithelium, hyperplastic and neoplastic malignant lesions of the breast.
Concha A; Ruiz-Cabello F; Cabrera T; Nogales F; Collado A; Garrido F
Eur J Immunogenet; 1995 Aug; 22(4):299-310. PubMed ID: 7495782
[TBL] [Abstract][Full Text] [Related]
17. High expression of the antigen recognized by the monoclonal antibody GB24 on human breast carcinomas: a preventive mechanism of malignant tumor cells against complement attack?
Hofman P; Hsi BL; Manie S; Fenichel P; Thyss A; Rossi B
Breast Cancer Res Treat; 1994; 32(2):213-9. PubMed ID: 7532466
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
